BIOGEN INC. 4

Accession 0001127602-17-009803

$BIIBCIK 0000875045operating

View on SEC.gov Company Profile

Filed

Mar 1, 7:00 PM ET

Accepted

Mar 2, 5:12 PM ET

Size

40.6 KB

Accession

0001127602-17-009803

Insider Transaction Report

Form 4

Period: 2017-02-28

BIOGEN INC.BIIB

DiPietro Kenneth

EVP Human Resources

Transactions

Other
Restricted Stock Unit
2017-02-28−1,216→ 2,676 total
Exercise: $0.00Exp: 2018-02-23→ Common Stock (1,216 underlying)
Exercise/Conversion
Restricted Stock Unit
2017-02-28−728→ 1,948 total
Exercise: $0.00Exp: 2018-02-23→ Common Stock (728 underlying)
Exercise/Conversion
Restricted Stock Unit
2017-02-28−1,494→ 5,392 total
Exercise: $0.00Exp: 2019-02-22→ Common Stock (1,494 underlying)
Exercise/Conversion
Restricted Stock Unit
2017-02-28−1,174→ 0 total
Exercise: $0.00Exp: 2017-02-12→ Common Stock (1,174 underlying)
Exercise/Conversion
Restricted Stock Unit
2017-02-28−2,300→ 1 total
Exercise: $0.00Exp: 2017-02-12→ Common Stock (2,300 underlying)
Other
Restricted Stock Unit
2017-02-28−1→ 0 total
Exercise: $0.00Exp: 2017-02-12→ Common Stock (1 underlying)
Exercise/Conversion
Common Stock
2017-02-28+1,174→ 6,513 total
Tax Payment
Common Stock
2017-02-28$274.76/sh−1,083$297,565→ 7,177 total
Other
Restricted Stock Unit
2017-02-28−1,378→ 1,174 total
Exercise: $0.00Exp: 2017-02-12→ Common Stock (1,378 underlying)
Other
Restricted Stock Unit
2017-02-28−1,198→ 6,886 total
Exercise: $0.00Exp: 2019-02-22→ Common Stock (1,198 underlying)
Exercise/Conversion
Common Stock
2017-02-28+728→ 4,665 total
Tax Payment
Common Stock
2017-02-28$287.63/sh−485$139,501→ 5,339 total
Tax Payment
Common Stock
2017-02-28$284.75/sh−335$95,391→ 4,330 total
Exercise/Conversion
Common Stock
2017-02-28+2,300→ 8,260 total
Exercise/Conversion
Common Stock
2017-02-28+1,494→ 5,824 total
Tax Payment
Common Stock
2017-02-28$274.76/sh−553$151,942→ 5,960 total

Footnotes (11)

[F1]This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017.
[F10]This award was previously reported as covering 2,249 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017
[F11]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
[F2]This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017.
[F3]This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017.
[F4]This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
[F5]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
[F6]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
[F7]This award was previously reported as covering 3,802 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017
[F8]This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017
[F9]This award was previously reported as covering 2,494 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017

Documents

2 files

Issuer

BIOGEN INC.

CIK 0000875045

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0000875045

Filing Metadata

Form type: 4
Filed: Mar 1, 7:00 PM ET
Accepted: Mar 2, 5:12 PM ET
Size: 40.6 KB

View on SEC.gov